The biomarkers market size is estimated to be USD 54,198.4 million in 2022 and is expected to witness a CAGR of 14.65% during the forecast period 2023-2033.  Higher incidence of chronic diseases, improvements in the methods used to develop biomarker-based diagnostics, and rising geriatric population are factors contributing to the market growth. Furthermore, recent developments in biomarkers, such as biomarker signatures and rising use of biomarkers in the diagnosis of infectious diseases is expected to support the market growth. However, higher capital expenditures and extended durations for biomarkers is expected to hinder the growth.

Recent developments in biomarkers, such as biomarker signatures is expected to propel the market growth. This has led to non-invasive testing, quicker drug development, and early diagnosis. For instance, Tetranectin can serve as a biomarker for the detection of heart failure, according to the Nature Journal in 2020. Similar to this, sTNFR2 was identified as a novel biomarker for the diagnosis of acute adult T-cell leukemia/lymphoma in 2020. Considering such discoveries and technical improvements, the market is predicted to grow profitably throughout the forecast period.

Rising use of biomarkers in the diagnosis of infectious diseases is predicted to spur the market. For instance, potential MicroRNA-based biomarkers for the identification of infections, such as influenza infections, rhinoviruses, HIV, TB, malaria, Ebola, and Hendra virus, have been discovered, according to Frontiers in Microbiology in 2020. The objective of these miRNA-based indicators is to promote the early emergence of infectious diseases.

Segmentation

By Type

The market is categorized into efficacy, safety, and validation. In 2022, the safety segment accounted for the highest revenue share due to increasing public awareness of the importance of regular health screenings, decrease in drug attrition rates, and increase in the population who are at a higher risk of contracting diseases such as cancer, cardiovascular disease, and kidney disorders. Preclinical safety assessment and drug development take less time and costs when safety biomarkers are used in preclinical trials to help identify drug candidates that are likely to be well-tolerated by humans. he validation biomarkers market is anticipated to develop at a second-fastest rate throughout the course of the forecast period due to their application in the pharmaceutical industry to forecast the therapeutic failure of pharmaceutical compounds with weak therapeutic profiles and distinctive genetic profiles

By Application

The market is categorized into drug discovery & development, personalized medicines, diagnostics, others. In the global market, the drug discovery & development segment accounted for the largest revenue share in 2022 owing to strong R&D investments for the creation of customised treatments, improved capacity to forecast drug efficacy, and a quick approval procedure. One such case is Halozyme, Inc.’s introduction of a targeted therapy for patients with Non-small Cell Lung Cancer (NSCLC) who have the EGFR mutation. The diagnostics segment is predicted to grow at the quickest pace over the projection period due to advantages in early-stage disease detection. his provides a chance for the diagnostic segment to promote early diagnosis and increase the rate of diagnosis.

By Disease

The market is segmented into cardiovascular disease, cancer, immunological disease, neurological disease, and others. In 2022, the cancer segment accounted for the largest revenue share owing to quick and precise diagnostic tools, increase in the incidence of cancer worldwide, and unmet requirement for more specific, customized therapy targets for cancer patients. The market is anticipated to be driven by its application in early cancer detection, prognosis estimation, and treatment response monitoring. According to the American Cancer Society, 1.8 million new cases of the disease were recorded in 2020, and 606,520 people in the country died unexpectedly from it.

Regional Markets

In 2022, North America region accounted for the highest revenue in the biomarkers market and is expected to maintain its dominance during the forecast period. This is attributed to the advantages in early-stage disease detection. This provides a chance for the diagnostic segment to promote early diagnosis and increase the rate of diagnosis. Europe is anticipated to be the second-largest market due to the existence of important research institutions and industry participants there. The expansion of partnerships between European institutions and providers of biomarker solutions is responsible for the market expansion. The market is anticipated to increase quickly as a result of the rapid expansion in the availability of biomarker testing.

Competitor Insights

Some of the key players operating in the biomarkers market are Siemens Healthineers AG, Abbott Laboratories, Bio-Rad Laboratories, Inc., Johnson & Johnson Services, Inc., Thermo Fisher Scientific, Inc., Epigenetics AG, F. Hoffmann-La Roche Ltd., and Qiagen.

To achieve a competitive edge, these businesses are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, Immunovia AB and CREATE Health Cancer Center collaborated to build a biomarker-based technology that can boost NGS’s sensitivity and spur the development and discovery of new biomarkers to address unmet requirements.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including type, application, and disease from 2023 to 2033.

Report Scope:

Segmentation: Biomarkers Market Report 2022 – 2033

Type (Revenue, USD Million), 2022 – 2033

• Efficacy
• Safety
• Validation

Application (Revenue, USD Million), 2022 – 2033

• Drug Discovery & Development
• Personalized Medicines
• Diagnostics
• Others

Disease (Revenue, USD Million), 2022 – 2033

• Cardiovascular Disease
• Cancer
• Immunological Disease
• Neurological Disease
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA